Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Glutamate receptors and pain.
Bleakman D, Alt A, Nisenbaum ES. Bleakman D, et al. Semin Cell Dev Biol. 2006 Oct;17(5):592-604. doi: 10.1016/j.semcdb.2006.10.008. Epub 2006 Oct 28. Semin Cell Dev Biol. 2006. PMID: 17110139 Review.
A role for AMPA receptors in mood disorders.
Alt A, Nisenbaum ES, Bleakman D, Witkin JM. Alt A, et al. Among authors: bleakman d. Biochem Pharmacol. 2006 Apr 28;71(9):1273-88. doi: 10.1016/j.bcp.2005.12.022. Epub 2006 Jan 24. Biochem Pharmacol. 2006. PMID: 16442080 Review.
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, O'Neill MJ. Murray TK, et al. Among authors: bleakman d. J Pharmacol Exp Ther. 2003 Aug;306(2):752-62. doi: 10.1124/jpet.103.049445. Epub 2003 May 2. J Pharmacol Exp Ther. 2003. PMID: 12730350
AMPA receptor potentiators for the treatment of CNS disorders.
O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. O'Neill MJ, et al. Among authors: bleakman d. Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):181-94. doi: 10.2174/1568007043337508. Curr Drug Targets CNS Neurol Disord. 2004. PMID: 15180479 Review.
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A, Ho KH, Jarvie K, Rizkalla G, Wright RA, Calligaro DO, Schoepp D, Mattiuz EL, Stratford RE, Johnson B, Salhoff C, Katofiasc M, Phebus LA, Schenck K, Cohen M, Filla SA, Ornstein PL, Johnson KW, Bleakman D. Weiss B, et al. Among authors: bleakman d. J Pharmacol Exp Ther. 2006 Aug;318(2):772-81. doi: 10.1124/jpet.106.101428. Epub 2006 May 11. J Pharmacol Exp Ther. 2006. PMID: 16690725
Anxiolytic-like effects through a GLUK5 kainate receptor mechanism.
Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE Jr, Witkin JM. Alt A, et al. Among authors: bleakman d. Neuropharmacology. 2007 Jun;52(7):1482-7. doi: 10.1016/j.neuropharm.2007.02.005. Epub 2007 Mar 2. Neuropharmacology. 2007. PMID: 17418283
92 results